TY - JOUR
T1 - Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
AU - on behalf of Global Obesity Collaborative
AU - Au, Kahei
AU - Zheng, Ming Hua
AU - Lee, Wei Jei
AU - Ghanem, Omar M.
AU - Mahawar, Kamal
AU - Shabbir, Asim
AU - le Roux, Carel W.
AU - Targher, Giovanni
AU - Byrne, Christopher D.
AU - Yilmaz, Yusuf
AU - Valenti, Luca
AU - Sebastiani, Giada
AU - Treeprasertsuk, Sombat
AU - Hui, Hannah Xiaoyan
AU - Sakran, Nasser
AU - Neto, Manoel Galvao
AU - Kermansaravi, Mohammad
AU - Kow, Lilian
AU - Seki, Yosuke
AU - Tham, Kwang Wei
AU - Dang, Jerry
AU - Cohen, Ricardo V.
AU - Stier, Christine
AU - AlSabah, Salman
AU - Oviedo, Rodolfo J.
AU - Chiappetta, Sonja
AU - Parmar, Chetan
AU - Yang, Wah
AU - Zuluaga, Mauricio Zuluaga
AU - Zhou, Xiao Dong
AU - Zhang, Le
AU - Zhang, Wen
AU - Zhang, Jinshan
AU - Zerrweck, Carlos
AU - Zakeri, Roxanna
AU - Yuan, Baowen
AU - Xu, Liang
AU - Xu, Pengfei
AU - Xia, Mingfeng
AU - Wijeratne, Thejana Kamil
AU - Wei, Zhuoqi
AU - Wang, Ke
AU - Wang, Ningjian
AU - Wafa, Ala
AU - Udomsawaengsup, Suthep
AU - Toumi, Zaher
AU - Tolone, Salvatore
AU - Tay, Kon Voi
AU - Sun, Dan Qin
AU - Sousa, Xavier
AU - Snoekx, Rob
AU - Shi, Yongpeng
AU - Shahmiri, Shahab Shahabi
AU - Seyedyousefi, Sarah
AU - Schumann, Roman
AU - Schneider, Romano
AU - Saviello, Cosimo
AU - Samadov, Elgun
AU - Saggu, Sukhvinder Singh
AU - Ruiz-Ucar, Elena
AU - Ruiz-Tovar, Jaime
AU - Rossi, Felipe Martin Bianco
AU - Rheinwalt, Karl Peter
AU - Rama Rao, Vittal Sree
AU - Rao, Ravi
AU - e Quinino, Reynaldo Martins
AU - Qi, Xingshun
AU - Pouwels, Sjaak
AU - Pournaras, Dimitri J.
AU - de Leon-Ballesteros, Guillermo Ponce
AU - Palermo, Mariano
AU - Omarov, Taryel Isgender
AU - Niyaz, Abdulellah Mohamedamin
AU - Ng, Stephen Ka kei
AU - Neimark, Aleksandr
AU - Miller, Karl Anton
AU - Merola, Giovanni
AU - Materazzo, Marco
AU - Martinez-Duartez, Pedro R.
AU - Marshall, Skye
AU - Liu, Yaming
AU - Lakdawala, Muffazal
AU - Lianas, Panagiotis
AU - Kosai, Nik Ritza
AU - Kalmoush, Abd Elfattah Morsi
AU - Ji, Fanpu
AU - Jaiswal, Richa
AU - Ingallinella, Sara
AU - Huang, Ang
AU - Hu, Songhao
AU - Hoff, Anna Carolina
AU - Hee, Yingli
AU - Han, Juqiang
AU - Hai, Li
AU - Ghazouani, Omar
AU - Gawdat, Khaled Aly
AU - Flores, Jose Eduardo Garcia
AU - Felsenreich, Daniel Moritz
AU - Fang, Tingyu
AU - Fan, Yu Chen
AU - Elkeleny, Mostafa Refaie
AU - Elghadban, Hosam M.
AU - Elfawal, Mohamad Hayssam
AU - Duan, Yi
AU - Demirel, Tugrul
AU - Dejeu, Viorel
AU - De Falco, Nadia
AU - Batista Dantas, Anna Carolina
AU - Costa-Pinho, Andre
AU - Chen, An Tian
AU - Chen, Tao
AU - Chai, Jin
AU - Cetinkunar, Suleyman
AU - Castillo Vacaflor, Patricia Yoshimia
AU - Calikoglu, Ismail
AU - Blackham, Ruth
AU - Bangash, Ali Haider
AU - Aykota, Muhammed Rasid
AU - Awad, Selmy S.
AU - athar, Rahmatullah
AU - Amr, Bassem
AU - Al-Momani, Hazem
AU - Ahmad, Suhaib
AU - Abu-Abeid, Adam
AU - Abou-Mrad, Adel Karim
AU - Abouelazayem, Mohamed
AU - Abdelbaki, Tamer Nabil
AU - Oviedo, Rodolfo J.
AU - Cohen, Ricardo V.
AU - le Roux, Carel W.
AU - Ghanem, Omar M.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Purpose of Review: The approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed. Recent Findings: Resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted. Summary: MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
AB - Purpose of Review: The approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed. Recent Findings: Resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted. Summary: MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
UR - http://www.scopus.com/inward/record.url?scp=85205576954&partnerID=8YFLogxK
U2 - 10.1007/s13679-024-00582-z
DO - 10.1007/s13679-024-00582-z
M3 - Review article
C2 - 39110384
AN - SCOPUS:85205576954
SN - 2162-4968
VL - 13
SP - 818
EP - 830
JO - Current Obesity Reports
JF - Current Obesity Reports
IS - 4
ER -
